World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

Abstract

CLINICAL PHARMACOLOGY OF INDOMETHACIN

Gian Maria Pacifici*

ABSTRACT

Indomethacin is a methylated indole derivative indicated for the treatment of moderate-to-severe rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gouty arthritis, and acute painful shoulder. Indomethacin is a potent nonselective inhibitor of cyclooxygenase, inhibits the motility of polymorphonuclear leukocytes, and depresses the biosynthesis of mucopolysaccharides. Indomethacin, administered intravenously at the dose of 0.1 to 0.25 mg/kg twice-daily for three doses, is used to close the patent ductus arteriosus in preterm neonates and in adults the intravenous dose of indomethacin is 100 mg twice-daily or thrice-daily. Indomethacin has an excellent bioavailability. The efficacy and safely, the prophylaxis, and the treatment with indomethacin, and the trials conducted with indomethacin have been reviewed. Indomethacin is O-demethylated by CYP2C9, CYP1A2, and by CYP2D6 and is conjugated with glucuronic acid by UGT1A1, UGT1A3, UGT1A9, and by UGT2B7. Indomethacin is an active metabolite of acemetacin. The pharmacokinetics of indomethacin have been studied in health volunteers following the administration of a single dose and multiple doses of 90 mg of acemetacin sustained-release tablets and acemetacin sustained-release capsules. The elimination half-life of indomethacin is about 10 hours following the administration of single and multiple doses of both acemetacin formulations. The interaction of indomethacin with drugs and the toxicity induced by indomethacin have been reviewed. The aim of this study is to review the efficacy and safely, the prophylaxis, and the treatment with indomethacin. In addition, the trials conducted with indomethacin, the metabolism, and the pharmacokinetics of indomethacin, the interaction of indomethacin with drugs, and the toxicity induced by indomethacin have been reviewed.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR